Global Autoimmune Disease Diagnostics Market and Forecast to 2030

GURUGRAM, India - Aug. 13, 2025 - PRLog -- The global autoimmune disease diagnostics market was valued at USD 6,583 Million in 2024, and the market is projected to reach USD 10,423 Million by 2030. Autoimmune diseases are characterized by an abnormal immune response in which the body produces antibodies that mistakenly attack its own cells and tissues, leading to the deterioration and destruction of healthy tissue. There are more than 80 known types of autoimmune diseases worldwide, including well-known conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis. Autoimmune diseases can be divided into two general groups: Organ specific, where the autoantibodies attack a specific organ, and Non-organ specific (or systemic), where the autoantibodies attack multiple organ systems. For example, in Hashimoto's thyroiditis, autoantibodies specifically target and damage the thyroid gland. In contrast, systemic autoimmune diseases involve multiple organ systems. A classic example is systemic lupus erythematosus (SLE), in which autoantibodies can affect a wide range of tissues and organs throughout the body.

The increasing incidence of conditions like rheumatoid arthritis and Hashimoto's thyroiditis, coupled with supportive government policies, is expected to significantly influence the growth of the autoimmune disease diagnostics market. According to the American Autoimmune Related Diseases Association, more than 50 million people in the United States are currently affected by autoimmune disorders. This number is projected to rise in the coming years. Consequently, the growing need for accurate and advanced diagnostic techniques, alongside the rising prevalence of these diseases, is anticipated to propel market expansion over the forecast period.

Recent Developments

• In April 2025, Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic products, launched its first molecular diagnostic product to optimize the prognosis of multiple myeloma.
• In February 2025, Biocon Biologics, a subsidiary of Biocon, launched YESINTEK (ustekinumab-kfce), a biosimilar option to Stelara (ustekinumab) in the US market. YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a cost-effective treatment for chronic autoimmune diseases.
• In December 2024, Quest Diagnostics introduced a revolutionary autoimmune disease diagnostic service that uses AI algorithms to analyze test results in real time, providing clinicians with instant feedback on patient status.

For more details, please visit: https://apeloconsulting.com/product/autoimmune-disease-di...